FDA 483 - Janssen Sciences Ireland UC - April 30, 2021

An FDA inspection of Janssen Sciences Ireland UC in Ringaskiddy, Co. Cork, Ireland, from April 26-30, 2021, identified a significant quality control deficiency. The firm failed to adequately investigate invalid assays, even when rates exceeded internal SOP thresholds. This indicates a lapse in their laboratory quality management and investigation processes.